

Fecha del CVA

11/02/2020

Parte A. DATOS PERSONALES

Nombre y Apellidos	José María Castellano Vázquez		
DNI/NIE/Pasaporte		Edad	
Núm. identificación del investigador	Researcher ID	L-8097-2014	
	Scopus Author ID		
	Código ORCID	0000-0003-3624-1298	

A.1. Situación profesional actual

Organismo	HM Hospitales		
Dpto. / Centro			
Dirección			
Teléfono		Correo electrónico	
Categoría profesional	Jefe de Estudios y Presidente de la Comisión de Docencia de Post-Grado de HM Hospitales	Fecha inicio	2018
Espec. cód. UNESCO			
Palabras clave			

A.2. Formación académica (título, institución, fecha)

Licenciatura/Grado/Doctorado	Universidad	Año
Doctorado en Medicina Cardiovascular	Universidad de Navarra	2010
Licenciado en Medicina	Universidad de Navarra	2004
Licenciado en Ciencias Biológicas	Brown University, Providence, RI, USA	1998

A.3. Indicadores generales de calidad de la producción científica

- Citas totales de 38 publicaciones indexadas en el WoS: 722 (19 citas/documento)
- Promedio de citas/año durante los últimos 5 años (2015-2019): 118,4
- Publicaciones totales en el primer cuartil (Q1): 24 (63%)
- Publicaciones totales en el primer decil (D1): 9 (26%)
- Índice H: 16

Parte B. RESUMEN LIBRE DEL CURRÍCULUM

Jose M. Castellano has a degree in Molecular Biology from Brown University, Providence, RI and a degree in medicine from the University of Navarra. He is specialized in Cardiology from the University Clinic of Navarra in 2010, obtaining his PhD in cardiovascular sciences in 2010. He later worked at the Mount Sinai Hospital in New York as Clinical Research Associate and obtained a postdoctoral fellowship in Advanced Clinical Research at the Mount Sinai School of Medicine under the direction of Dr. Valentin Fuster. Since 2014 he is Coordinator of Clinical Research at the Spanish National Center for Cardiovascular Research (CNIC). Currently he is Director of the Customized Cardiovascular Health Program at the Integrated Center for Cardiovascular Diseases of the Montepincipe University Hospital, where he carries out his clinical activity. Dr. Castellano is Associate Professor at the Mount Sinai School of Medicine and Associate Professor of the Faculty of Medicine of the San Pablo CEU University, where he teaches the subjects of Cardiology and Introduction to Translational Research. His main research activities include population health, cardiovascular imaging, and pharmacological treatment of ischemic heart disease, among others. He was the Scientific Coordinator and first author of the FOCUS study. Currently he is co-PI of the SECURE study, funded by the H2020 program of the European Commission as well as co-Pi of the TANSNIP study. He is author of several book chapters and has been invited as speaker at the events organized by the most important national and international societies of Cardiology (AHA, ACC, ESC, ESH, Inter-American Society of Internal Medicine, Inter-American Society of Cardiology).

Parte C. MÉRITOS MÁS RELEVANTES (ordenados por tipología)

C.1. Publicaciones

- 1 **Artículo científico.** Acin-Perez, R.; et al. 2018. Ablation of the stress protease OMA1 protects against heart failure in mice Sci Transl Med. 10-434, pp.eaan4935-eaan4935. ISSN 1946-6234.
- 2 **Artículo científico.** Castellano Vazquez, J. M.2017. From Risk Scales to Subclinical Atherosclerosis Quantification Through Non-invasive Imaging: Toward a New Paradigm in Cardiovascular Risk Prediction Rev Esp Cardiol. 70-7, pp.532-4. ISSN 1885-5857 (Electronic); 1885-5857 (Linking).
- 3 **Artículo científico.** Webster, R.; Castellano, J. M.; Onuma, O. K.2017. Putting polypills into practice: challenges and lessons learned Lancet. 389-10073, pp.1066-1074. ISSN 1474-547X (Electronic); 0140-6736 (Linking).
- 4 **Artículo científico.** Bansilal, S.; et al. 2016. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes J Am Coll Cardiol. 68-8, pp.789-801. ISSN 1558-3597 (Electronic); 0735-1097 (Linking).
- 5 **Artículo científico.** Castellano, J. M.; et al. 2014. A polypill strategy to improve adherence: results from FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Project J Am Coll Cardiol. 64-20, pp.2071-82. ISSN 1558-3597 (Electronic); 0735-1097 (Linking).
- 6 **Artículo científico.** Castellano, J. M.; et al. 2012. Anticoagulation during pregnancy in patients with a prosthetic heart valve Nat Rev Cardiol. 9-7, pp.415-24. ISSN 1759-5010 (Electronic); 1759-5002 (Linking).

C.2. Proyectos

- 1 TANSNIP (Trans-atlantic Network to Study Stepwise Noninvasive Imaging as a Tool for Cardiovascular Prognosis & Prevention) Valentín Fuster. (Madrid). 06/01/2014-28/02/2020.
- 2 SECURE (Secondary Prevention of Cardiovascular Disease in the Elderly) Valentín Fuster. (Unión Europea (H2020 PHC 17)). 18/01/2015-18/01/2020. 6.000.000 €.
- 3 Translational Research Program in Cardio-oncology at CNIC: Prediction, early detection, mechanism and treatment of chemotherapy-induced cardiotoxicity in oncologic patients José Antonio Enríquez Domínguez. (FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III). 01/06/2017-31/12/2019.
- 4 FOCUS (Fixed-dose Combination Drug for Secondary Cardiovascular Prevention) Valentín Fuster. (Unión Europea (7th Framework Programme)). 01/01/2012-01/01/2015.
- 5 Coronary Revascularization in Diabetic Patients, Follow-up Valentín Fuster. (Nueva York). 01/01/2014-31/12/2014.
- 6 HHM (Healthy Hearts México) Valentín Fuster. (Madrid y México). Desde 01/01/2016.
- 7 Progression of Early Subclinical Atherosclerosis (PESA) (FUNDACION CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III).

C.3. Contratos

C.4. Patentes